Davis Polk & Wardwell / UNITED STATES
provides a qualitative rating based on Partner's clients feedback assessment
The indicator measures the ability to convey information to another effectively and efficiently.
The indicator measures knowledge of, and skill in the exercise of, practices required for successful accomplishment of a business, job, or task.
The indicator measures the comparison of what is actually performed with what can be achieved with the same consumption of resources.
The indicator measures the degree to which objectives are achieved and the extent to which targeted problems are solved.
Perceived Added Value
The indicator measures the evaluation of the difference between the cost of the tax / legal counsel and the contribution of the professional to achieve the business objectives of the matter.
Unity Biotechnology's $85 Million Initial Public OfferingDavis Polk advised the representatives of the several underwriters in connection with an initial public offering of 5,000,000 shares of common stock of Unity Biotechnology, Inc.
Pure Storage's $500 Million Convertible Senior Notes OfferingDavis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Pure Storage, Inc. of $500 million aggregate principal amount of its 0.125% convertible senior notes due 2023.
Accelerate Diagnostics, Inc's $150 Million Convertible Senior Notes OfferingDavis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Accelerate Diagnostics, Inc. of $150 million aggregate principal amount of its 2.50% convertible senior notes due 2023.
Atara Biotherapeutics, Inc. $302 Million Follow-On OfferingsDavis Polk advised the joint book-running managers and representatives of the several underwriters in connection with two SEC-registered follow-on offerings of common stock of Atara Biotherapeutics, Inc., the first of which was for $140 million and closed on January 9, 2018, and the second of which was for $162 million and closed on March 5, 2018.
Seattle Genetics' $600 Million Equity OfferingDavis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,269,230 shares of common stock, which includes 1,730,769 shares of common stock sold pursuant to the exercise of the underwriters’ over-allotment option.
Results are based upon public information and may undervalue a law firm's and/or a lawyer's professional experience and client portfolio.